Last reviewed · How we verify

NCT06804876

COMBO Endoscopy Oropharyngeal Airway in Sedated Gastrointestinal Endoscopy for Obese Patients

Completed Phase 2 Last updated 21 May 2025
What this trial tests

Phase 2 trial testing the COMBO Endoscopy Oropharyngeal Airway in Hypoxia in 107 participants. Completed in 26 March 2025.

Timeline
4 February 2025
Primary endpoint
26 March 2025
26 March 2025

Quick facts

Lead sponsorZhejiang University
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment107
Start date4 February 2025
Primary completion26 March 2025
Estimated completion26 March 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Zhejiang University

Who can join

Adults 18 to 70, any sex, with Hypoxia or Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing gastrointestinal endoscopy with propofol. This is particularly true for obese patients, who have a higher incidence of hypoxia. A recent innovation in this domain is the COMBO Endoscopy Oropharyngeal Airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway management. This device has been purposefully designed to cater to the unique requirements of endoscopic procedures. The principal objective of this study is to assess the efficacy of the COMBO Endoscopy Oropharyngeal Airway in reducing the incidence of hypoxia in obese patients undergoing gastrointestinal endoscopy under sedation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of the COMBO Endoscopy Oropharyngeal Airway

Trials testing the same drug.

Other recruiting trials for Hypoxia

Currently open trials in the same condition.

Other Zhejiang University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06804876.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing